New brain imaging agent could improve Alzheimer's detection

NCT ID NCT06439992

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new radioactive tracer called 18F-Fluselenamyl for PET scans to safely detect amyloid plaques in the brain, a hallmark of Alzheimer's disease. Researchers will compare it to an existing tracer in 60 healthy volunteers and people with mild cognitive impairment or Alzheimer's. The goal is to see if the new tracer is safe and effective for diagnosing Alzheimer's.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALZHEIMER DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Alzheimer disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Email: •••••@•••••

Locations

  • Washington University School of Medicine

    RECRUITING

    St Louis, Missouri, 63110, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••